CXCL10/gamma interferon-inducible protein 10-mediated protection against Leishmania amazonensis infection in mice.
Leishmania amazonensis can cause progressive disease in most inbred strains of mice. We have previously shown that L. amazonensis-infected C57BL/6 mice have profound impairments in expression of proinflammatory cytokines and chemokines and in activation of antigen-specific CD4(+) T cells. These impairments are independent of interleukin-4 (IL-4) but partially due to IL-10 production. The precise mechanism of pathogenesis associated with L. amazonensis infection remains largely unresolved. Since chemokines are essential mediators of leukocyte recruitment and effector cell function, we hypothesized that these molecules are important for the initiation of early responses locally and for the eventual control of the infection. In this study, we examined the roles of CXCL10/gamma interferon-inducible protein 10 (IP-10) and CCL2/monocyte chemoattractant protein 1 (MCP-1) in the activation of the macrophage effector function in vitro and their efficacy in ameliorating infection in vivo. Bone marrow-derived macrophages of both BALB/c and C57BL/6 mice were treated with increasing concentrations of recombinant chemokines prior to infection with either stationary-phase promastigotes or tissue-derived amastigotes. We found that treatment with IP-10 or MCP-1 significantly reduced parasite burdens, in a dose-dependent manner, and triggered nitric oxide production. When susceptible C57BL/6 mice were injected locally with IP-10 following L. amazonensis infection, there was a significant delay in lesion development and a reduction in parasite burdens, accompanied by 7- and 3.5-fold increases in gamma interferon and IL-12 secretion, respectively, in restimulated lymph node cells. This study confirms that IP-10 plays a protective role in promoting the reduction of intracellular parasites and thereby opens new avenues for therapeutic control of nonhealing cutaneous leishmaniasis in the New World.
Vasquez
Rene E
RE
Department of Microbiology and Immunology, University of Texas Medical Branch, Medical Research Building 3.132, 301 University Blvd., Galveston, TX 77555-1070, USA.
Soong
Lynn
L
D000818:Animals; D001854:Bone Marrow Cells / Q000276:immunology; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000008:administration & dosage / Q000032:analysis; D054357:Chemokine CXCL10; D019743:Chemokines, CXC / Q000008:administration & dosage* / Q000032:analysis; D016207:Cytokines / Q000378:metabolism; D007267:Injections; D007371:Interferon-gamma / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D007891:Leishmania; D007896:Leishmaniasis / Q000276:immunology / Q000517:prevention & control*; D008198:Lymph Nodes / Q000187:drug effects / Q000276:immunology; D008262:Macrophage Activation; D008264:Macrophages / Q000737:chemistry; D051379:Mice; D009569:Nitric Oxide / Q000378:metabolism; D018417:Th1 Cells / Q000276:immunology
C491768:Ccl2 protein, mouse; D018932:Chemokine CCL2; D054357:Chemokine CXCL10; D019743:Chemokines, CXC; D016207:Cytokines; D018664:Interleukin-12; D009569:Nitric Oxide; D007371:Interferon-gamma